# A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors

> **NCT05735366** · PHASE1 · COMPLETED · sponsor: **Chugai Pharmaceutical** · enrollment: 22 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** SAIL66

## Key facts

- **NCT ID:** NCT05735366
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-17
- **Primary completion:** 2026-01-26
- **Final completion:** 2026-01-26
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05735366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05735366, "A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05735366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*